Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Feb 2017 · 1 min read
In brief
In brief
Prospective genomic sequencing of 72 histiocytosis patients identified actionable mutations including BRAF V600E, MAP2K1 variants, and novel BRAF deletions resistant to standard inhibitors. Targeted therapies with dabrafenib or trametinib produced dramatic responses in refractory multisystem LCH cases, supporting routine genomic profiling at diagnosis.
Written by the GCMD Library team from the article.
Statements in this article
Biopsies of 72 patients with a variety of histiocytoses underwent comprehensive genomic profiling with targeted DNA and RNA sequencing.
Fifteen patients (21%) carried the known BRAF V600E mutation.
Eleven patients (15%) carried various mutations in MAP2K1, which induce constitutive activation of extracellular signal-regulated kinase (ERK) and were sensitive to inhibitors of mitogen-activated protein kinase kinase (MEK).
Four LCH patients had an uncommon in-frame deletion in BRAF (N486_P490del or N486_T491>K), resulting in constitutive activation of ERK with resistance to V600E-specific inhibitors.
Recurring ALK rearrangements were identified in histiocytoses.
Patients with aggressive multisystem LCH experienced dramatic and sustained responses to monotherapy with either dabrafenib or trametinib.
Comprehensive genomic profiling should be regularly applied to histiocytic disorders at diagnosis.
Comprehensive genomic profiling can positively impact clinical care in histiocytic disorders.